Hemophilia A: all 885 studies

Page 2 of 9. Open to participants first (139), then studies with results posted, then the rest; newest registration first within each.

• Dynamics of the Anti-factor VIII Antibody Signature During Treatment With EmicizumabRecruitingNCT05802836
• A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)Enrolling by invitationNCT05768386
• Gene Therapy for Hemophilia B Patients Aged 12-18 Years OldRecruitingNCT05709288Phase 1
• A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B PatientsRecruitingNCT05641610Phase 1/2
• The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.RecruitingNCT05630651Not applicable
• A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia BRecruitingNCT05611801Phase 3
• Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B RespectivelyRecruitingNCT05568719Phase 3
• The Efficacy and Safety of ZS802 in Chinese Hemophilia A Patients.RecruitingNCT05523128Not applicable
• Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia ARecruitingNCT05500807Phase 1
• A Study of FVIII Gene Therapy for Hemophilia ARecruitingNCT05454774Early Phase 1
• Safety and Tolerability of VGB-R04 in Patients With Haemophilia BRecruitingNCT05152732Early Phase 1
• Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without InhibitorsRecruitingNCT05145127Phase 3
• Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab ProphylaxisRecruitingNCT05022459
• The World Federation of Hemophilia Gene Therapy RegistryNot yet recruitingNCT04883710
• Liver Biopsy In Haemophilia Gene TherapyRecruitingNCT04817462Not applicable
• Gene Therapy for Chinese Hemophilia ARecruitingNCT04728841Not applicable
• Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa PegolEnrolling by invitationNCT04682145
• ASC618 Gene Therapy in Hemophilia A PatientsRecruitingNCT04676048Phase 1/2
• SEVENFACT® for Bleeding Events in Hemophilia With InhibitorsRecruitingNCT04647227Phase 4
• National Longitudinal Cohort of Hematological DiseasesRecruitingNCT04645199
• A Study Following Males With Haemophilia A on Prophylaxis With Esperoct®Enrolling by invitationNCT04574076
• Hemlibra in Mild Hemophilia ARecruitingNCT04567511Phase 4
• SAFE Study: Safety of aPCC Following Emicizumab ProphylaxisRecruitingNCT04563520Phase 3
• Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia ANot yet recruitingNCT04418414Phase 1
• ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic DisordersRecruitingNCT04398628
• Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)RecruitingNCT04278404
• Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia ARecruitingNCT04131036
• Treatment of Hemophilia A Patients With FVIII InhibitorsRecruitingNCT04023019
• Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia A Patients.RecruitingNCT03947567Phase 4
• Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A PatientsRecruitingNCT03695978
• Patient Reported Outcomes Burdens and Experiences - Phase 3RecruitingNCT03549858
• World Bleeding Disorders RegistryRecruitingNCT03327779
• Lentiviral FVIII Gene TherapyNot yet recruitingNCT03217032Phase 1
• The European Paediatric Network for Haemophilia Management ( PedNet Registry)RecruitingNCT02979119
• German Pediatric Hemophilia Research DatabaseRecruitingNCT02912143
• Does the Thrombin Generation Test Performed During the Pharmacokinetic Profile of the Substitutive Factor VIII Bring Benefits to the Personalized Treatment of Pediatric Patients and Adult Hemophilia A Patients Under Prophylaxis ?RecruitingNCT02803502Not applicable
• Swiss Hemophilia RegistryRecruitingNCT02512250
• Global Haemostatic Methods Following Administration of Bypassing Agents to Patients With Haemophilia With InhibitorsRecruitingNCT02453542
• A Survey on the Success of Inhibitor Elimination Using Individualized Concentrate Selection and Controlled ITIRecruitingNCT02207894
• Low-Cost Platelet-Rich Plasma for HemarthropathyCompletedNCT06543368Not applicableResults posted
• An 18-month Low-interventional Study to Assess Joint Health in Haemophilia A and B Patients on Prophylaxis With Efmoroctocog Alfa or Eftrenonacog AlfaTerminatedNCT05856266Phase 4Results posted
• A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia ACompletedNCT05707351Phase 3Results posted
• Safety and Efficacy of FVIIa to Prevent Excessive Bleeding in Hemophilia Patients With Inhibitors Undergoing Major SurgeryTerminatedNCT05695391Phase 3Results posted
• A Proof-of-concept Study to Reduce Treatment Burden in Haemophilia Participants Receiving Factor VIII and Factor IX InfusionsCompletedNCT05437211Not applicableResults posted
• A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the BloodCompletedNCT05147662Phase 3Results posted
• Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)CompletedNCT05082116Phase 3Results posted
• Prophylaxis Regimen for Hemophilia A PatientsCompletedNCT05036278Phase 4Results posted
• A Study of ADVATE in People With Hemophilia A in IndiaCompletedNCT04985682Phase 4Results posted
• A Study of TAK-660 in Surgical Procedures for People With Hemophilia A.CompletedNCT04941898Results posted
• Study to Evaluate Safety and Tolerability of a Single Dose of PF-06741086 in Chinese Adult Participants With Severe HemophiliaCompletedNCT04878731Phase 1Results posted
• Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia ACompletedNCT04759131Phase 3Results posted
• An Exploration of the Impact of Emicizumab on the Lives of People With Haemophilia and Inhibitors and Their FamiliesCompletedNCT04723693Results posted
• Study of TAK-672 in Participants With Acquired Hemophilia ACompletedNCT04580407Phase 2/3Results posted
• A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia ACompletedNCT04565236Phase 4Results posted
• Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia ATerminatedNCT04541628Phase 1/2Results posted
• A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without InhibitorsActive, not recruitingNCT04431726Phase 3Results posted
• Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Hemophilia A PatientsCompletedNCT04396639Phase 4Results posted
• A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B SubjectsTerminatedNCT04394286Phase 1/2Results posted
• Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A AdultsActive, not recruitingNCT04370054Phase 3Results posted
• Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia ACompletedNCT04323098Phase 3Results posted
• The Hemophilia Inhibitor Eradication TrialTerminatedNCT04303572Phase 3Results posted
• The Hemophilia Inhibitor Prevention TrialTerminatedNCT04303559Phase 3Results posted
• Nonacog Alfa Prophylaxis And Treatment Of Bleeding Episodes In Previously Treated Patients With Hemophilia BCompletedNCT04286412Phase 4Results posted
• An Observational Study to Evaluate Physical Activity, Bleeding Incidence and Health Related Quality of Life, in Participants With Haemophilia A Without Inhibitors Receiving Standard of Care TreatmentCompletedNCT04165135Results posted
• A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia ACompletedNCT04161495Phase 3Results posted
• A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII InhibitorsCompletedNCT04158648Phase 3Results posted
• Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophilia A (Post-marketing Investigation)CompletedNCT04085458Phase 4Results posted
• Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With HemophiliaCompletedNCT04072237Phase 1Results posted
• Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia ATerminatedNCT04046848Phase 1/2Results posted
• Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia BCompletedNCT03995784Phase 2Results posted
• Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia BCompletedNCT03938792Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia BActive, not recruitingNCT03861273Phase 3Results posted
• Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia BCompletedNCT03855280Phase 3Results posted
• Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII InhibitorsCompletedNCT03734588Phase 1/2Results posted
• Multiple Escalating Dose Study of BAY1093884 in Adults With Hemophilia A or B With or Without InhibitorsTerminatedNCT03597022Phase 2Results posted
• Evaluation of Safety Following Immune Tolerance Induction Treatment With Turoctocog Alfa in Patients With Haemophilia A Following Inhibitor Development in NN7170-4213 TrialTerminatedNCT03588741Phase 3Results posted
• A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)CompletedNCT03587116Phase 3Results posted
• HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B PatientsCompletedNCT03569891Phase 3Results posted
• RIXUBIS PMS India (RIXUBIS PMS)CompletedNCT03565237Phase 4Results posted
• A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent ProphylaxisCompletedNCT03549871Phase 3Results posted
• A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia ACompletedNCT03528551Phase 3Results posted
• Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5TerminatedNCT03520712Phase 1/2Results posted
• Dose Confirmation Trial of AAV5-hFIXco-PaduaCompletedNCT03489291Phase 2Results posted
• Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alfa for a 8 Weeks PeriodCompletedNCT03449342Phase 4Results posted
• A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without InhibitorsCompletedNCT03417245Phase 3Results posted
• A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With InhibitorsCompletedNCT03417102Phase 3Results posted
• Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and BCompletedNCT03407651Phase 2Results posted
• Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kgCompletedNCT03392974Phase 3Results posted
• A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese VolunteersCompletedNCT03380780Phase 1Results posted
• Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia ACompletedNCT03376516Phase 3Results posted
• Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301)CompletedNCT03370913Phase 3Results posted
• A Study of BAX 888 in Male Adults With Severe Hemophilia ACompletedNCT03370172Phase 1/2Results posted
• A Factor IX Gene Therapy Study (FIX-GT)TerminatedNCT03369444Phase 1/2Results posted
• PF-06741086 Long-term Treatment in Severe HemophiliaCompletedNCT03363321Phase 2Results posted
• Study of Emicizumab Prophylaxis in Participants With Hemophilia A With or Without Inhibitors Undergoing Minor Surgical ProceduresTerminatedNCT03361137Phase 4Results posted
• Immune Tolerance Induction in Haemophilia A Patients Using Wilate or NuwiqTerminatedNCT03344003Results posted
• Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A ParticipantsCompletedNCT03315455Phase 3Results posted
• Understanding Hemophilia A and B Drug Dosage Administration PatternsTerminatedNCT03248141Results posted
• A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)CompletedNCT03205163Phase 1/2Results posted
• INdividualized ITI Based on Fviii(ATE) Protection by VWFTerminatedNCT03204539Phase 4Results posted

← Hemophilia A overview